Tomas Kazda, M.D., Ph.D. – Young Investigator of the LEGATO Project
Tomas Kazda is the Director of Research, Science, and Education at the Masaryk Memorial Cancer Institute in Brno, Czechia, and the Chief of the Radiotherapy Program for Brain Tumors at the same institution. He is a member of several scientific boards and expert committees, including the EORTC Brain Tumor Group. He graduated from Masaryk University, […]
The objectives of the LEGATO Project in the words of Principal Investigator and Co-Leader Prof. Dr Matthias Preusser
LEGATO is part of a series of clinical trials funded by the Horizon Europe programme as part of the EU Mission on Cancer. The twelve clinical trials, led by multistakeholder and multidisciplinary consortiums, form together the European Cancer Cluster. In this video, the project’s Principal Investigator and Co-Leader, Prof. Dr Matthias Preusser from the Medical […]
Introducing the Clinical Trial leaders of the LEGATO Project, Prof. Dr Matthias Preusser and Prof. Dr Giuseppe Minniti
Over the last couple of months, we introduced the people and organisations behind the LEGATO Project on our social media platforms. In this article, we will focus on the project’s clinical trial leader, Prof. Dr Matthias Preusser, and the clinical trial co-leader, Prof. Dr Giuseppe Minniti. Dr Preusser is Professor of Medical Oncology and Head of […]
Official start of project LEGATO
The European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are delighted to announce the official start of LEGATO, a pragmatic phase III clinical trial focusing on recurrent Glioblastoma. This is the first official trial looking into the potential benefits of chemo-irradiation compared to chemotherapy alone to improve disease control […]
Three new EORTC clinical trials funded by the EU
Brussels, April 24, 2023 – The European Commission has approved the funding of three new research projects coordinated by EORTC. Thanks to these grants, EORTC will perform three innovative pragmatic clinical trials optimising treatments for patients with refractory cancers starting summer of 2023. Public funding is essential to address clinically relevant questions with no commercial interest […]
